Physician profile
Sue M Mitchell
NPI 1730271503
$2,460.59
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $636 · 2021: $287.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.93 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $436.72 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.97 | 2019-2021 | |
| Gilead Sciences, INC. | $205.98 | 2019-2020 | |
| Qol Medical, LLC | $178.02 | 2019-2020 | |
| Pfizer INC. | $114.35 | 2019-2020 | |
| Intuitive Surgical, INC. | $112.90 | 2019 | |
| Shionogi INC | $76.52 | 2019 | |
| Endo Pharmaceuticals INC. | $65.89 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $51.10 | 2019 | |
| Allergan, INC. | $50.12 | 2019 | |
| Ironwood Pharmaceuticals, INC | $30.98 | 2019-2020 | |
| Janssen Biotech, INC. | $30.83 | 2019 | |
| Alfasigma USA, INC. | $29.14 | 2020 | |
| Daiichi Sankyo INC. | $26.11 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.61 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.58 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.16 | 2021 | |
| Oxford Immunotec USA INC | $12.68 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.